-
1.发明公开Molecules with extended half-lives, compositions and uses thereof 审中-公开MolekülemitlängerenHalbwertszeiten，Zusammensetzungen und deren Verwendung
公开(公告)号：EP2341060A1
公开(公告)日：2011-07-06
申请号：EP10010679.8
申请日：2001-12-12
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的分子，包括IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂，其具有一个 或更多的增加FcRn的恒定结构域或片段的亲和力的氨基酸修饰。 具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断中使用较少量和/或更少频率给药的优点。
-
2.发明公开
公开(公告)号：EP2289550A2
公开(公告)日：2011-03-02
申请号：EP10007381.6
申请日：2001-01-26
申请人： MedImmune, LLC
发明人： Young, James F. , Johnson, Leslie S. , Huse, William D. , Wu, Herren , Watkins, Jeffrey D. , Koenig, Scott
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/1027 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： Ultra high affinity antibodies with binding affinities in the range of 10 10 M -1 , and even 10 11 M -1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.
摘要翻译： 公开了具有10 10 M -1，甚至10 11 M -1范围内的结合亲和力的超高亲和力抗体。 这样的抗体包括具有新型高亲和力互补决定区（CDR）的抗体，特别是具有衍生自人或小鼠的骨架和恒定区的抗体。 还公开了制备和筛选这些抗体的方法，以及使用它们预防和/或治疗疾病，特别是病毒诱导的疾病的方法。
-
公开(公告)号：EP2357187A1
公开(公告)日：2011-08-17
申请号：EP10010681.4
申请日：2001-12-12
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的分子，包括IgG，非IgG免疫球蛋白，蛋白质和非蛋白质剂，所述分子具有一个 或更多增加恒定结构域或片段对FcRn的亲和力的氨基酸修饰。 具有增加的半衰期的此类蛋白质和分子具有在治疗，预防或诊断使用此类分子时需要更少量和/或更少频率给药的优点。
-
公开(公告)号：EP2341075A1
公开(公告)日：2011-07-06
申请号：EP10010678.0
申请日：2001-03-01
发明人： Young, James F. , Koenig, Scott , Johnson, Leslie S. , Huse, William D. , Wu, Herren , Watkins, Jeffry D.
IPC分类号： C07K16/00 , C07K16/10 , A61K39/395 , A61P31/00
CPC分类号： C07K16/1027 , A61K2039/505 , C07K16/00 , C07K2317/567
摘要： High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for production of high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.
-
5.发明公开Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment 审中-公开用于预防和治疗管理/剂量的抗RSV抗体的方法
公开(公告)号：EP2338512A1
公开(公告)日：2011-06-29
申请号：EP10010675.6
申请日：2001-11-28
申请人： MedImmune, LLC
发明人： Young, James F. , Koenig, Scott , Johnson, Leslie S. , Watkins, Jeffry D. , Huse, William D. , Wu, Herren
IPC分类号： A61K39/395 , A61K39/42 , A61K39/00 , A61K39/155 , C12Q1/70
CPC分类号： C07K16/1027 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565
摘要： The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.; The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a SRV antigen, and methods using said compositions for detection or diagnosis a RSV infection.
-
6.发明公开Molecules with extended half-lives, compositions and uses thereof 有权新泽西州的MUSA MITLÄNGERENHALBWERTSZEITEN，ZUSAMMENSETZUNGEN UND DEREN VERWENDUNG
公开(公告)号：EP2354149A1
公开(公告)日：2011-08-10
申请号：EP10010680.6
申请日：2001-12-12
CPC分类号： C07K16/283 , A61K38/00 , A61K39/00 , A61K47/48507 , A61K47/6835 , A61K49/0002 , A61K49/0004 , A61K2039/505 , C07K2/00 , C07K14/70503 , C07K16/00 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/94 , C07K2319/00 , C07K2319/30 , Y10S435/81
摘要： The present invention provides molecules, including IgGs, non-lgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
摘要翻译： 本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂的分子，其具有一个 或更多的增加FcRn的恒定结构域或片段的亲和力的氨基酸修饰。 具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断中使用较少量和/或更少频率给药的优点。
-
公开(公告)号：EP2341060B1
公开(公告)日：2019-02-20
申请号：EP10010679.8
申请日：2001-12-12
-
公开(公告)号：EP2289550A3
公开(公告)日：2012-02-15
申请号：EP10007381.6
申请日：2001-01-26
申请人： MedImmune, LLC
发明人： Young, James F. , Johnson, Leslie S. , Huse, William D. , Wu, Herren , Watkins, Jeffrey D. , Koenig, Scott
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/1027 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： Ultra high affinity antibodies with binding affinities in the range of 10 10 M -1 , and even 10 11 M -1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.
-
9.发明公开ANTIBODIES BINDING TO THE F PROTEIN OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) 审中-公开抗体与呼吸道合胞病毒（RSV）的F蛋白结合
公开(公告)号：EP2341074A1
公开(公告)日：2011-07-06
申请号：EP10010677.2
申请日：2001-03-01
发明人： Young, James F. , Koenig, Scott , Johnson, Leslie S. , Huse, William D. , Wu, Herren , Watkins, Jeffry D.
IPC分类号： C07K16/00 , C07K16/10 , A61K39/395 , A61P31/00
CPC分类号： C07K16/1027 , A61K2039/505 , C07K16/00 , C07K2317/567
摘要： High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for production of high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.
摘要翻译： 公开了具有高动力学结合速率常数和任选的高亲和力的高效价抗体，包括其免疫活性片段，以及用于产生此类抗体的方法。 本文公开的高效价抗体是中和或非中和类型，并且对由微生物，特别是病毒显示的抗原以及存在于癌细胞和各种类型的毒素上的抗原性位点以及毒素产物具有特异性。 还描述了生产高效中和抗体和增加现有中和抗体的效力的方法。 公开了使用所述抗体预防和/或治疗疾病，特别是由病毒诱发或引起的疾病的方法。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.025 秒)
